OVER-ALL RESPONSE OF INDUCTION CHEMOTHERAPY IN PATIENTS OF LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY, OROPHARYNX, AND LARYNX AT ONCOLOGY DEPARTMENT JINNAH HOSPITAL, LAHORE
DOI:
https://doi.org/10.18623/rvd.v23.5978Palabras clave:
Induction Chemotherapy, Locally Advanced Squamous Cell Carcinoma, Head And Neck Cancer, Oral Cavity Carcinoma, Oropharyngeal Carcinoma, Laryngeal Carcinoma, Carboplatin And Paclitaxel, Overall Response RateResumen
Background: Oral cavity, oropharynx, and larynx locally advanced squamous cell carcinoma (SCC) poses a great therapeutic challenge because of heavy tumor burden and functional impairment. Induction chemotherapy (IC) is becoming an increasingly popular way of downstaging tumors and enhancing the treatment. The purpose of this research was to assess the response to the induction chemotherapy in general in the patients of the Jinnah Hospital, Lahore, with locally advanced SCC. Objective: To identify the Over-all response of induction chemotherapy in patients with locally advanced squamous cell carcinoma of the oral cavity, Oropharynx and larynx in Jinnah Hospital, Lahore. Methods: This case series was a descriptive case series done in Oncology Department of Jinnah Hospital, Lahore from November 2025 to February 2026. Non-probability consecutive sampling was used to enroll 87 chemotherapy-naïve patients aged 1870 years with Stage III-IV SCC and ECOG performance status of 0-2. The patients were treated with induction chemotherapy consisting of carboplatin (AUC 3) and paclitaxel (125mg/m 2) after every two weeks during three cycles. At the 13th week, the response of tumors was evaluated through contrast-enhanced CT scans based on the criteria of RECIST 1.1. ORR was determined as the percentage of patients who had a complete response (CR) or partial response (PR). Results: Tumor responses were categorized as CR, PR, stable disease (SD), and progressive disease (PD). The overall response rate (CR + PR) was analyzed along with stratification for age, gender, tumor site, stage, and ECOG status. Statistical analysis was performed using SPSS version 26, and associations were assessed using the Chi-square test. Conclusion: Induction chemotherapy is shown to have a high overall response rate in patients with locally advanced SCC of the oral cavity, oropharynx and larynx, and therefore induction chemotherapy is an effective neoadjuvant treatment modality in clinical practice.
Citas
Abdelmeguid AS, Silver NL, Boonsripitayanon M, Glisson BS, Ferrarotto R, Gunn GB, et al. Role of induction chemotherapy for oral cavity squamous cell carcinoma. Cancer. 2021;127(17):3107–12.
Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP, Kowalski LP, et al. Prognostic performance of current stage III oral cancer patients after curative intent resection: evidence to support a revision of the American Joint Committee on Cancer staging system. Annals of Surgical Oncology. 2015 Dec;22(Suppl 3):985–91.
Barbosa-Martins J, Rolo A, Lima B, Pereira JC, Araújo C, Guimarães J, et al. Efficacy and safety of induction chemotherapy in oral cavity cancer: an eight-year experience at a Portuguese reference center. Tumori. 2024 Oct;110(5):340–7.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018 Nov 1;68(6):394–424.
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-048): a randomized, open-label, phase 3 study. The Lancet. 2019;394(10212):1915–1928.
Ferrarotto R, Gillison ML. Molecular mechanisms of response and resistance in head and neck squamous cell carcinoma. Nature Reviews Clinical Oncology. 2022;19(3):143–156.
Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatments for advanced laryngeal cancer. Journal of Clinical Oncology. 2013;31(7):845–852.
Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. The Lancet Oncology. 2017;18(8):1022–39.
Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Annals of Oncology. 2018 May;29(5):1130–40.
Harrington KJ, Burtness B, Greil R, Soulieres D, Tahara M, de Castro G Jr, et al. Pembrolizumab for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma: updated analysis of KEYNOTE-048. Journal of Clinical Oncology. 2023;41(6):127–137.
Lacas B, Bourhis J, Overgaard J, Zhang Q, Gregoire V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on individual patient data. The Lancet Oncology. 2021;22(3):e103–e112.
Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2020;31(11):1462–1475.
Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clinic Proceedings. 2016:386–96.
Mehanna H, Robinson M, Hartley A, Kong A, Forster M, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus–positive oropharyngeal cancer (De-ESCALaTE HPV): a randomized phase 3 trial. The Lancet. 2019;393(10166):51–60.
Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-012 study. Journal of Clinical Oncology. 2018;36(15):1410–1418.
Pignon JP, Bourhis J, Domenge C, Designé L, Hill C, Adelstein DJ, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. The Lancet. 2000;355(9208):949–55.
Rana A, Rana P, Gupta M, Seam R, Gupta M. Conventional chemoradiation vs. induction chemotherapy followed by conventional chemoradiation for locally advanced head and neck cancer: a prospective randomized study. World Academy of Sciences Journal. 2020;2(6):1–8.
Szturz P, Vermorken JB. Treatment of elderly patients with squamous cell carcinoma of the head and neck. Frontiers in Oncology. 2016;6:199.
Taberna M, Mena M, Pavón MA, Alemany L, Gillison ML, Mesía R. Human papillomavirus-related oropharyngeal cancer. Annals of Oncology. 2017;28(10):2386–98.
Vermorken JB, Remenar E, van Herpen CML, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. The New England Journal of Medicine. 2007;357(17):1695–1704.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
I (we) submit this article which is original and unpublished, of my (our) own authorship, to the evaluation of the Veredas do Direito Journal, and agree that the related copyrights will become exclusive property of the Journal, being prohibited any partial or total copy in any other part or other printed or online communication vehicle dissociated from the Veredas do Direito Journal, without the necessary and prior authorization that should be requested in writing to Editor in Chief. I (we) also declare that there is no conflict of interest between the articles theme, the author (s) and enterprises, institutions or individuals.
I (we) recognize that the Veredas do Direito Journal is licensed under a CREATIVE COMMONS LICENSE.
Licença Creative Commons Attribution 3.0
